AstraZeneca’s (AZN) “Overweight” Rating Reiterated at JPMorgan Chase & Co.

JPMorgan Chase & Co. restated their overweight rating on shares of AstraZeneca (LON:AZN) in a report published on Wednesday morning, Marketbeat.com reports.

A number of other brokerages have also issued reports on AZN. Shore Capital reiterated a “buy” rating on shares of AstraZeneca in a research note on Thursday, November 7th. Berenberg Bank reiterated a “buy” rating and set a GBX 140 ($1.76) target price on shares of AstraZeneca in a research report on Monday, January 27th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of GBX 7,542.80 ($94.91).

AstraZeneca Stock Performance

Shares of AZN opened at £117.04 ($147.28) on Wednesday. The stock has a market capitalization of £225.19 billion, a P/E ratio of 32.08, a P/E/G ratio of 0.86 and a beta of 0.17. The company has a debt-to-equity ratio of 73.83, a quick ratio of 0.59 and a current ratio of 0.93. AstraZeneca has a 1 year low of GBX 9,670 ($121.68) and a 1 year high of £133.88 ($168.47). The company’s fifty day moving average is £109.53 and its two-hundred day moving average is £114.64.

AstraZeneca Company Profile

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.